162 related articles for article (PubMed ID: 28139868)
1. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N
Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868
[TBL] [Abstract][Full Text] [Related]
2. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
3. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
4. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.
De Brakeleer S; De Grève J; Loris R; Janin N; Lissens W; Sermijn E; Teugels E
Hum Mutat; 2010 Mar; 31(3):E1175-85. PubMed ID: 20077502
[TBL] [Abstract][Full Text] [Related]
5. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
6. Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Ratajska M; Antoszewska E; Piskorz A; Brozek I; Borg Å; Kusmierek H; Biernat W; Limon J
Breast Cancer Res Treat; 2012 Jan; 131(1):89-97. PubMed ID: 21344236
[TBL] [Abstract][Full Text] [Related]
7. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
8. Literature Review of
Alenezi WM; Fierheller CT; Recio N; Tonin PN
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
[TBL] [Abstract][Full Text] [Related]
9. Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.
Ratajska M; Matusiak M; Kuzniacka A; Wasag B; Brozek I; Biernat W; Koczkowska M; Debniak J; Sniadecki M; Kozlowski P; Klonowska K; Pilyugin M; Wydra D; Laurent G; Limon J; Irminger-Finger I
Oncol Rep; 2015 Nov; 34(5):2609-17. PubMed ID: 26329992
[TBL] [Abstract][Full Text] [Related]
10. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
11. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.
Karppinen SM; Heikkinen K; Rapakko K; Winqvist R
J Med Genet; 2004 Sep; 41(9):e114. PubMed ID: 15342711
[No Abstract] [Full Text] [Related]
12. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
[TBL] [Abstract][Full Text] [Related]
13. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.
Thai TH; Du F; Tsan JT; Jin Y; Phung A; Spillman MA; Massa HF; Muller CY; Ashfaq R; Mathis JM; Miller DS; Trask BJ; Baer R; Bowcock AM
Hum Mol Genet; 1998 Feb; 7(2):195-202. PubMed ID: 9425226
[TBL] [Abstract][Full Text] [Related]
15. Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
Tavera-Tapia A; Pérez-Cabornero L; Macías JA; Ceballos MI; Roncador G; de la Hoya M; Barroso A; Felipe-Ponce V; Serrano-Blanch R; Hinojo C; Miramar-Gallart MD; Urioste M; Caldés T; Santillan-Garzón S; Benitez J; Osorio A
Breast Cancer Res Treat; 2017 Feb; 161(3):597-604. PubMed ID: 27913932
[TBL] [Abstract][Full Text] [Related]
16. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
[TBL] [Abstract][Full Text] [Related]
17. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
[TBL] [Abstract][Full Text] [Related]
19. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Sabatier R; Adélaïde J; Finetti P; Ferrari A; Huiart L; Sobol H; Chaffanet M; Birnbaum D; Bertucci F
Genes Chromosomes Cancer; 2010 Dec; 49(12):1143-51. PubMed ID: 20842729
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
